Mark Jean Gnoth - Concepedia

Concepedia

Author

Mark Jean Gnoth

Bayer (Germany)

Also Known As

M GNOTH, M J Gnoth, M.J Gnoth, M.J. Gnoth, Mark Gnoth, Mark J Gnoth, Mark J. Gnoth, Mark Jean Gnoth, Mark J. Gnoth

29

Publications

1.4K

Citations

14

H-Index

27

Concepts

All Affiliations

Bayer (Germany)Max Planck Institute of Molecular Physiology Universität Hamburg University Medical Center Hamburg-Eppendorf

MJ

About

Mark Jean Gnoth is an author at Bayer (Germany) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	460
2	Biochemistry	4	4	148
3	Natural Sciences	2	2	61
4	Biomolecular Engineering	2	2	35
5	Chemical Biology	1	1	39

Mark Jean Gnoth

×

15

Publications

1.4K

Citations

14

H-Index

	Year	Citations
Human Milk Oligosaccharides Are Minimally Digested In Vitro Mark Jean Gnoth, Clemens Kunz, E. Kinne‐Saffran, Journal of Nutrition NutritionIn Vitro FermentationFood DigestionGlycobiologyBiotechnology	2000	297
Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling Rio Dumitrascu, Hossein Ardeschir Ghofrani, Eva Dony, Circulation	2006	219
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban Mark Jean Gnoth, Ulf Buetehorn, Uwe Muenster, Journal of Pharmacology and Experimental Therapeutics	2011	214
Investigations of the in Vitro Transport of Human Milk Oligosaccharides by a Caco-2 Monolayer Using a Novel High Performance Liquid Chromatography-Mass Spectrometry Technique Mark Jean Gnoth, Silvia Rudloff, Clemens Kunz, Journal of Biological Chemistry	2001	106
Soluble Guanylate Cyclase Activator Reverses Acute Pulmonary Hypertension and Augments the Pulmonary Vasodilator Response to Inhaled Nitric Oxide in Awake Lambs Oleg V. Evgenov, Fumito Ichinose, Natalia V. Evgenov, Circulation	2004	101
Inhaled Agonists of Soluble Guanylate Cyclase Induce Selective Pulmonary Vasodilation Oleg V. Evgenov, Daniel S. Kohane, Kenneth D. Bloch, American Journal of Respiratory and Critical Care Medicine	2007	75
Characterization of Substrates and Inhibitors for the In Vitro Assessment of Bcrp Mediated Drug–Drug Interactions Uwe Muenster, Birgit Grieshop, Karsten Ickenroth, Pharmaceutical Research Molecular PharmacologyDrug TargetBiochemistryDrug ResistanceMedicine	2008	74
Cardiovascular effects of a novel potent and highly selective azaindole‐based inhibitor of Rho‐kinase R. Kast, Hartmut Schirok, Santiago Figueroa‐Pérez, British Journal of Pharmacology	2007	65
Sorafenib Hepatobiliary Disposition: Mechanisms of Hepatic Uptake and Disposition of Generated Metabolites Brandon Swift, Noelia Nebot, Jin Kyung Lee, Drug Metabolism and Disposition	2013	58
In Vitro to In Vivo Comparison of the Substrate Characteristics of Sorafenib Tosylate toward P-Glycoprotein Mark Jean Gnoth, Steffen Sandmann, Katrin Engel, Drug Metabolism and Disposition	2010	41

Page 1